Clinical advances in the management of myelodysplastic syndrome (MDS), such as the integration of refined risk stratification schemas to the magnitude of emerging data for novel therapeutic agents, hold the potential to transform patient outcomes. Catch all of the latest evidence, featuring dynamic discussions from leading experts regarding the placement of emerging therapies into personalized treatment plans for patients with MDS, with a focus on federal, public, and government healthcare settings.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/risk-adapted-treatment-plans-myelodysplastic-syndrome-advancing-evidence-based
- Start Date: 2024-11-22 06:00:00
- End Date: 2024-11-22 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 6250.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 9375.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 7437.5 - Is Kind Support: False Source: Sobi - Amount: 6250.0 - Is Kind Support: False Source: Taiho Pharmaceutical - Amount: 12437.5 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest